BioMarin Pharma (NASDAQ: BMRN) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

BioMarin (BMRN) Buy Rating Maintained at BofA/Merrill Lynch; FDA Vote Suggests Drisapersen Efficacy Was 'Inconclusive'November 25, 2015 7:27 AM BioMarin (BMRN) FDA Panel Deals with Two Opposing Views - WedbushNovember 25, 2015 7:08 AM BioMarin Pharma (BMRN) will resume trading at 7:10am ETNovember 25, 2015 6:53 AM BioMarin (BMRN) Panel Negative, But Less than FDA - BairdNovember 25, 2015 6:50 AM BioMarin (BMRN) FDA Panel a 'Drisaster' - OppenheimerNovember 25, 2015 6:46 AM FDA Advisory Committee Discusses Clinical Data Package for BioMarin’s Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingNovember 24, 2015 6:55 PM BioMarin Pharma (BMRN) dystrophin data don't affect trial results - Bloomberg, Citing FDA PanelNovember 24, 2015 5:03 PM BioMarin Pharma's (BMRN) Drisapersen Phase 2 Issues Don't Affect Findings - FDA PanelNovember 24, 2015 3:42 PM UPDATE: BioMarin Pharma's (BMRN) First Drisapersen Phase 2 has Issues - FDA PanelNovember 24, 2015 3:09 PM BioMarin Pharma (BMRN) Posts FDA Committee Meeting Presentation on DrisapersenNovember 24, 2015 10:05 AM